RECRUITING

Understanding Immunity to the Flu Vaccine in COVID-19 Patients

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to measure immunity to the flu vaccine over time in patients who have had COVID-19 and may have other medical conditions including obesity, type 2 diabetes, chronic fatigue, or long-term COVID-19 symptoms. Adults and children (age 9 to 64) who had been diagnosed with COVID-19 as well as controls without COVID-19 will be invited to participate in this study.

Official Title

Understanding Immunity to the Flu Vaccine in COVID-19 Patients

Quick Facts

Study Start:2020-10-29
Study Completion:2026-04
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04579588

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:9 Years to 64 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 9 through 64 years
  2. * Diagnosed with COVID-19 at least 2 months prior enrollment
  3. * Patients with or without obesity, diabetes, chronic fatigue and/or long term COVID-19 symptoms
  4. * Patients without COVID-19 diagnosis for controls
  1. * Received the influenza vaccine less than 4 months ago
  2. * Pregnant or lactating
  3. * Patients with special risks attendant to venipuncture
  4. * Use of immunomodulatory medications that may impact vaccine immune response per clinician's judgment
  5. * Contraindication to the flu vaccine
  6. * Immunodeficiency or autoimmune disease that may impact vaccine immune responses per clinician's judgement

Contacts and Locations

Study Contact

SNP Center Inquiry
CONTACT
(650) 521-7237
snpcenterallergy_inquiry@stanford.edu

Principal Investigator

Sayantani Sindher, MD
PRINCIPAL_INVESTIGATOR
Stanford University

Study Locations (Sites)

Stanford University
Palo Alto, California, 94304
United States

Collaborators and Investigators

Sponsor: Stanford University

  • Sayantani Sindher, MD, PRINCIPAL_INVESTIGATOR, Stanford University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-10-29
Study Completion Date2026-04

Study Record Updates

Study Start Date2020-10-29
Study Completion Date2026-04

Terms related to this study

Additional Relevant MeSH Terms

  • Corona Virus Infection
  • Flu Vaccine
  • Immunity